Combination therapy for HCV infection
A technology of VX-497 and dosage, applied in the field of combination therapy for HCV infection, can solve problems such as defects
Inactive Publication Date: 2006-12-20
VERTEX PHARMA INC
View PDF6 Cites 2 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
[0010] Combination of pegylated interferon and ribavirin, although effective, has pitfalls
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
Embodiment Construction
[0112] A 24-week, double-blind, randomized, placebo-controlled study of 31 patients non-responsive to ribavirin / Peg-Intron therapy. Patients were divided into three groups. All three groups received ribavirin / Peg-Intron therapy. One group was given placebo, while the second group was given VX-497 25 mg bid. A third group was administered VX-497 at doses according to the invention.
[0113] More than 80% of patients in the third group receiving ribavirin, Peg-Intron, and VX-497 at doses according to the invention achieved undetectable HCV RNA levels at the end of 24 weeks.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More PUM
Login to View More Abstract
The present invention relates to therapeutic combinations comprising VX-497, ribavirin, and interferon. The present invention also relates to methods using the therapeutic combinations of the present invention for treating HCV infection or alleviating one or more symptoms thereof in a patient. The present invention also provides kits comprising the combinations of the present invention.
Description
technical field [0001] The present invention relates to therapeutic combinations comprising VX-497, ribavirin and interferon. The present invention also relates to methods of treating HCV infection or alleviating one or more symptoms thereof in a patient using the therapeutic combinations of the present invention. The invention also provides kits comprising the therapeutic combinations of the invention. The invention also provides pharmaceutical regimens for administering the therapeutic combinations of the invention. Background technique [0002] HCV is an RNA virus belonging to the flavivirus family. Acute infection with HCV causes generally mild, often asymptomatic acute hepatitis. However, at least 85% of patients infected with HCV do not completely clear the virus and develop chronic infection of the liver. Once chronic hepatitis C is established, spontaneous clearance of the virus rarely occurs, and most patients with chronic hepatitis C slowly develop progressive ...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More Application Information
Patent Timeline
Login to View More Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/422A61K31/7056A61K38/21A61P31/14A61P1/16
CPCA61K38/212A61K38/21A61K31/422A61K31/7056A61P1/16A61P31/14A61P43/00A61K2300/00
Inventor E·埃特J·J·阿拉姆R·S·考夫曼
Owner VERTEX PHARMA INC